We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BOSTON—We caught up with BIO board chair and Alnylam CEO John Maraganore at this year's meeting and asked him about a range of topics, from preserving innovation and urgency as a biotech company grows to Alnylam's pricing plan for its gene-silencing thera